<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121410">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01522183</url>
  </required_header>
  <id_info>
    <org_study_id>M11-001</org_study_id>
    <nct_id>NCT01522183</nct_id>
  </id_info>
  <brief_title>Atypcial Hemolytic-Uremic Syndrome (aHUS) Registry</brief_title>
  <official_title>An Observational, Non-Interventional, Multi-Center, Multi-National Study of Patients With aTypical Hemolytic-Uremic Syndrome (aHUS Registry)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INC Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-marketing safety data on patients treated and untreated with eculizumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will capture post-marketing safety data on patients treated with eculizumab.
      Additionally, the study will collect information on the progression of disease in all
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who experience specified events</measure>
    <time_frame>10 years</time_frame>
    <description>To collect and evaluate safety and effectiveness data specific to the use of eculizumab in aHUS patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to first and subsequent occurrence of specified events.</measure>
    <time_frame>10 years</time_frame>
    <description>To assess the long term manifestations of thrombotic microangiopathy (TMA) complications of aHUS as well as other clinical outcomes, including morbidity and mortality in aHUS patients, receiving eculizumab treatment or other disease management approaches</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Atypical Hemolytic-Uremic Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Male or female patients of any age, including minors, who have been diagnosed with aHUS;
        clinical diagnosis of aHUS, patients with or without an identified complement regulatory
        factor genetic abnormality or anti-complement factor antibody, ADAMTS13 &gt; 5% (if
        performed)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients of any age, including minors, who have been diagnosed with
             aHUS

          -  Able to give written informed consent. Patient or patient's parent/legal guardian
             must be willing and able to given written informed consent and the patient (if minor)
             must be willing to give written informed assent [if applicable as determined by the
             central Institutional Review Boards/Independent Ethics Committees (IRB/IEC)].

          -  ADAMTS13 &gt; 5%, if performed.

        Exclusion Criteria:

          -  Hemolytic Uremic Syndrome (HUS) only due to Shiga Toxin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masayo Ogawa, MD, FAACP</last_name>
    <role>Study Director</role>
    <affiliation>Alexion Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Project Manager</last_name>
    <email>ahus-registry@incresearch.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 17, 2017</lastchanged_date>
  <firstreceived_date>January 18, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atypical Hemolytic-Uremic Syndrome</keyword>
  <keyword>aHUS</keyword>
  <keyword>Thrombotic Microangiopathy</keyword>
  <keyword>TMA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
    <mesh_term>Azotemia</mesh_term>
    <mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
    <mesh_term>Atypical Hemolytic Uremic Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
